Vor Biopharma Inc
For the period ended Dec 31, 2023. Filed Mar 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 20, 2024
VOR$19.56-2.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED StatementS of Cash Flows
| Year EndedDecember 31, | ||
|---|---|---|
| (in thousands) | 2023 | 2022 |
| Cash flows from operating activities | ||
| Net loss | $(117,863) | $(92,094) |
| Adjustments to reconcile net loss to net cash used in operations: | ||
| Depreciation expense | 3,492 | 2,525 |
| Non-cash lease expense | 4,727 | 3,578 |
| Stock-based compensation | 13,362 | 10,695 |
| Interest amortization on marketable securities | (4,660) | (12) |
| Changes in operating assets and liabilities: | ||
| Operating lease liabilities, net | (3,583) | (10,454) |
| Prepaid expenses and other current assets | 3,270 | 225 |
| Accounts payable and accrued liabilities | 2,850 | 1,114 |
| Other assets | (1,887) | (721) |
| Net cash used in operating activities | (100,292) | (85,144) |
| Cash flow from investing activities | ||
| Purchases of marketable securities | (74,923) | (123,189) |
| Proceeds from maturities of marketable securities | 147,000 | 37,560 |
| Purchases of property and equipment | (1,069) | (8,462) |
| Net cash provided by (used in) investing activities | 71,008 | (94,091) |
| Cash flow from financing activities | ||
| Proceeds from the issuance of common stock from public offering and concurrent private placement, net of underwriter fees and issuance costs | — | 111,524 |
| Payment of issuance costs related to underwritten public offering and concurrent private placement | (717) | — |
| Proceeds from the issuance of common stock from at-the-market sales agreements, net of issuance costs | 4,578 | 4,451 |
| Shares repurchased for tax withholdings upon vesting of restricted stock unit awards | (1,187) | — |
| Proceeds from stock option exercises and the issuance of shares under ESPP | 264 | 1,165 |
| Net cash provided by financing activities | 2,938 | 117,140 |
| Net decrease in cash, cash equivalents and restricted cash equivalents | (26,346) | (62,095) |
| Cash, cash equivalents and restricted cash equivalents, beginning of period | $60,119 | $122,214 |
| Cash, cash equivalents and restricted cash equivalents, end of period | $33,773 | $60,119 |
| Supplemental disclosure of non-cash activities | ||
| Right-of-use assets obtained in exchange for lease obligations | $— | $23,376 |
| Purchases of property and equipment in accounts payable and accrued liabilities | $70 | $38 |
| Financing costs associated with the sale of common stock included in accounts payable and accrued expenses | $27 | $812 |
A reconciliation of the cash, cash equivalents and restricted cash reported within the consolidated balance sheets that sum to the total of the same amounts shown in the statements of cash flows is as follows:
| December 31, | ||
|---|---|---|
| (in thousands) | 2023 | 2022 |
| Cash and cash equivalents | $31,360 | $57,706 |
| Restricted cash equivalents | 2,413 | 2,413 |
| Total cash, cash equivalents and restricted cash equivalents as shown on the statements of cash flows | $33,773 | $60,119 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.